Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 77,500 KRW
Change Today -1,400.00 / -1.77%
Volume 1.3M
068270 On Other Exchanges
Symbol
Exchange
KOSDAQ
OTC US
As of 2:29 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

celltrion inc (068270) Snapshot

Open
78,700
Previous Close
78,900
Day High
79,900
Day Low
77,200
52 Week High
04/14/15 - 97,400
52 Week Low
12/12/14 - 35,476
Market Cap
8.6T
Average Volume 10 Days
1.6M
EPS TTM
837.00
Shares Outstanding
111.0M
EX-Date
12/29/14
P/E TM
92.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLTRION INC (068270)

Related News

No related news articles were found.

celltrion inc (068270) Related Businessweek News

No Related Businessweek News Found

celltrion inc (068270) Details

Celltrion, Inc. researches, develops, manufactures, and sells biopharmaceutical products in South Korea and internationally. It develops and manufactures biosimilar monoclonal antibodies (mAbs) and therapeutics for oncology and autoimmune diseases. The company markets Remsima, a biosimilar mAb and tumor necrosis factor antagonist that is used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, plaque psoriasis, and psoriatic arthritis. Its product pipeline includes CT-P6 for the treatment of breast cancer; CT-P10 for the treatment of non- Hodgkin’s lymphoma and rheumatoid arthritis; and CT-P27, a therapeutic antibody for treatment against universal influenza, which has completed Phase IIA clinical trials. The company is also jointly developing mAbs for rabies with the Center for Disease Control and Prevention in the United States; antibodies against various virus subtypes and drug resistant hepatitis B viruses; Anti–GP88, mAbs for treatment of breast and lung cancer diseases; antibody-drug conjugate. In addition, it offers contract manufacturing services to biopharmaceutical companies. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Founded in 2002

celltrion inc (068270) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celltrion inc (068270) Key Developments

Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2014

Celltrion, Inc. reported earnings results for the full year ended December 31, 2014. For the period, the company reported sales of KRW 404,621,867,934, operating income of KRW 195,764,018,071, income from continuing operations before income tax of KRW 162,201,484,097, income from continuing operation and net income of KRW 128,060,383,547 against sales of KRW 224,575,287,050, operating income of KRW 100,983,544,044, income from continuing operations before income tax of KRW 116,766,418,113, income from continuing operation and net income of KRW 103,754,409,098 a year ago.

Celltrion, Inc., Annual General Meeting, Mar 20, 2015

Celltrion, Inc., Annual General Meeting, Mar 20, 2015., at 10:00 Korea Standard Time. Location: Songdo Convensia Yeonsugu songdodong 6-1 second floor meeting room. Agenda: To consider approval of financial statements based on the second bill; to consider appointment of inside directors; to consider appointment of Audit Committee; to consider approval of director remuneration bill; and to consider approval of stock option grant.

Celltrion, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM

Celltrion, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Seung-Seo Hong, Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
068270:KS 77,500.00 KRW -1,400.00

068270 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 068270.
View Industry Companies
 

Industry Analysis

068270

Industry Average

Valuation 068270 Industry Range
Price/Earnings 69.6x
Price/Sales 14.3x
Price/Book 6.3x
Price/Cash Flow 72.7x
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLTRION INC, please visit www.celltrion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.